Diabetes research and clinical practice · 2026
Lipidomics analysis to assess metabolic complications in familial partial lipodystrophy type 2.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koue-Chon-Lim Julie, Beyene Habtamu B, Giles Corey, Treiber Guillaume, Mellett Natalie A, Liang Amy, Cinel Michelle, Couret David, Cogne Muriel, Meilhac Olivier, Simonson Mathilde, Veeren Bryan, Meikle Peter J, Nobécourt Estelle, Huynh Kevin
Аннотация
AIMS: Familial Partial Lipodystrophy type 2 (FPLD2) is a severe form of metabolic syndrome associated with marked insulin resistance and complications like lipoatrophic diabetes. The aim of this study was to use lipidomics to better understand metabolic complications in FPLD2 and the benefit of the lipidomic-derived metabolic BMI score (mBMI) to characterize metabolic risk.
METHODS: A total of 115 adults with FPLD2 due to the LMNA 'Reunionese' variant and 289 unaffected age and sex matched adults were enrolled. Lipidomic analysis (787 lipid species) was performed using liquid chromatography-tandem mass spectrometry.
RESULTS: For FPLD2 subjects, among the 181 significant lipids species, ceramides, triglycerides, diacylglycerol were higher and plasmalogen, phosphatidylcholine, sphingolipids were lower regarding the control group (P < 0.05). The lipidomic signature of type 2 diabetes was reproduced in the control group with type 2 diabetes but also in lipoatrophic diabetes. We found mBMI was higher in the FPLD2 group especially individuals whose BMI fell within the normal range.
CONCLUSION: Lipidomic analyses reveal different species in control and FPLD2 groups, and the signature for type 2 diabetes coincide with the one for lipoatrophic diabetes. Moreover, the mBMI can be useful to assess metabolic health in FPLD2, especially individuals with normal BMI.
METHODS: A total of 115 adults with FPLD2 due to the LMNA 'Reunionese' variant and 289 unaffected age and sex matched adults were enrolled. Lipidomic analysis (787 lipid species) was performed using liquid chromatography-tandem mass spectrometry.
RESULTS: For FPLD2 subjects, among the 181 significant lipids species, ceramides, triglycerides, diacylglycerol were higher and plasmalogen, phosphatidylcholine, sphingolipids were lower regarding the control group (P < 0.05). The lipidomic signature of type 2 diabetes was reproduced in the control group with type 2 diabetes but also in lipoatrophic diabetes. We found mBMI was higher in the FPLD2 group especially individuals whose BMI fell within the normal range.
CONCLUSION: Lipidomic analyses reveal different species in control and FPLD2 groups, and the signature for type 2 diabetes coincide with the one for lipoatrophic diabetes. Moreover, the mBMI can be useful to assess metabolic health in FPLD2, especially individuals with normal BMI.